No abstract

For uplink large-scale MIMO systems, minimum mean square error (MMSE) algorithm is near-optimal but involves matrix inversion with high complexity. In this paper, we propose to exploit the Gauss-Seidel (GS) method to iteratively realize the MMSE algorithm without the complicated matrix inversion. To further accelerate the convergence rate and reduce the complexity, we propose a diagonal-approximate initial solution to the GS method, which is much closer to the final solution than the traditional zero-vector initial solution. We also propose a approximated method to compute log-likelihood ratios (LLRs) for soft channel decoding with a negligible performance loss. The analysis shows that the proposed GS-based algorithm can reduce the computational complexity from O(K 3 ) to O(K 2 ), where K is the number of users. Simulation results verify that the proposed algorithm outperforms the recently proposed Neumann series approximation algorithm, and achieves the near-optimal performance of the classical MMSE algorithm with a small number of iterations.Index Terms-Large-scale MIMO, signal detection, minimum mean square error (MMSE), Gauss-Seidel (GS) method, low complexity.

No abstract

No abstract

Background Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is under investigation for the reduction of recurrent C. difficile infection. Methods A randomized, double-blind, placebo-controlled, phase III study, with a Bayesian primary analysis integrating data from a previous phase IIb study, was conducted. Adults who had one or more C. difficile infection recurrences with a positive stool assay for C. difficile and who were previously treated with standard-of-care antibiotics were randomly assigned 2:1 to receive a subsequent blinded, single-dose enema of RBX2660 or placebo. The primary endpoint was treatment success, defined as the absence of C. difficile infection diarrhea within 8 weeks of study treatment. ResultsOf the 320 patients screened, 289 were randomly assigned and 267 received blinded treatment (n = 180, RBX2660; n = 87, placebo). Original model estimates of treatment success were 70.4% versus 58.1% with RBX2660 and placebo, respectively. However, after aligning the data to improve the exchangeability and interpretability of the Bayesian analysis, the model-estimated treatment success rate was 70.6% with RBX2660 versus 57.5% with placebo, with an estimated treatment effect of 13.1% and a posterior probability of superiority of 0.991. More than 90% of the participants who achieved treatment success at 8 weeks had sustained response through 6 months in both the RBX2660 and the placebo groups. Overall, RBX2660 was well tolerated, with manageable adverse events. The incidence of treatment-emergent adverse events was higher in RBX2660 recipients compared with placebo and was mostly driven by a higher incidence of mild gastrointestinal events. Conclusions RBX2660 is a safe and effective treatment to reduce recurrent C. difficile infection following standard-of-care antibiotics with a sustained response through 6 months.